Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension

Experimental Lung Research

Volumn 37, Issue 1, 2011, Pages 26-34

  Robbins, Ivan M ^a   Hemnes, Anna R ^a   Simon Gibbs, J ^b   Christman, Brian W ^a   Howard, Luke ^b   Meehan, Sharon ^b   Cabrita, Ines ^b   Gonzalez, Rochelle ^a   Oyler, Tracy ^a   Zhao, Lan ^b   Du, Rui Hong ^a   Mendes, Lisa A ^a   Wilkins, Martin R ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

nitric oxide; nitric oxide synthase; pulmonary hypertension; recoupling; tetrahydrobiopterin

Indexed keywords

AMBRISENTAN; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; SAPROPTERIN; SILDENAFIL;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL ARTICLE; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEART FUNCTION; HUMAN; HYPERTHYROIDISM; HYPOTENSION; INFLAMMATION; MALE; NAUSEA; OXIDATIVE STRESS; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SWELLING; TREATMENT RESPONSE; WALKING;

ADMINISTRATION, ORAL; ADULT; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BIOPTERIN; CHEMOKINE CCL2; DRUG THERAPY, COMBINATION; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LONDON; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NITRIC OXIDE; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; RECEPTORS, ENDOTHELIN; RECOVERY OF FUNCTION; SULFONES; TENNESSEE; TIME FACTORS; TREATMENT OUTCOME; WALKING;

EID: 79251493500     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902148.2010.512972     Document Type: Article

References (40)

1. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M: Cellular and molecular pathobi-ology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:13S-24S.
2. Cella G, Bellotto F, Tona F, Sbarai A, Mazzaro G, Motta G, Fareed J: Plasma markers of endothelial dysfunction in pul-monary hypertension. Chest. 2001;120:1226-1230.
3. Stamler JS, Loh E, Roddy MA, Currie KE, Creager MA: Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation. 1994;89: 2035-2040.
4. Demoncheaux EA, Higenbottam TW, Kiely DG, Wong JM, Wharton S, Varcoe R, Siddons T, Spivey AC, Hall K, Gize AP: Decreased whole body endogenous nitric oxide production in patients with primary pulmonary hypertension. J Vasc Res. 2005;42:133-136.
5. Girgis RE, Champion HC, Diette GB, Johns RA, Permutt S, Sylvester JT: Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. Am J Respir Crit Care Med. 2005;172:352-357.
6. Rolla G, Colagrande P, Scappaticci E, Chiavassa G, Dutto L, Cannizzo S, Bucca C, Morello M, Bergerone S, Bardini D, Zaccagna A, Puiatti P, Fava C, Cortese G: Exhaled nitric oxide in systemic sclerosis: relationships with lung involvement and pulmonary hypertension. J Rheumatol. 2000;27:1693-1698.
7. Kaneko FT, Arroliga AC, Dweik RA, Comhair SA, Laskowski D, Oppedisano R, Thomassen MJ, Erzurum SC: Biochemical reaction products of nitric oxide as quantitative markers of pri-mary pulmonary hypertension. Am J Respir Crit Care Med. 1998;158:917-923.
8. Andrew PJ, Mayer B: Enzymatic function of nitric oxide syn-thases. Cardiovasc Res. 1999;43:521-531.
9. Palmer RM, Ashton DS, Moncada S: Vascular endothe-lial cells synthesize nitric oxide from L-arginine. Nature. 1998;333:664-666.
10. Katusic ZS: Vascular endothelial dysfunction: does tetrahy-drobiopterin play a role? Am J Physiol Heart Circ Physiol. 2001;281:H981-H986.
11. Khoo JP, Zhao L, Alp NJ, Bendall JK, Nicoli T, Rockett K, Wilkins MR, Channon KM: Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation. 2005;111:2126-2133.
12. Robbins IM, Morrow JD, Christman BW: Oxidant stress but not thromboxane decreases with epoprostenol therapy. Free Radic Biol Med. 2005;38:568-554.
13. Bowers R, Cool C, Morphy RC, Tuder RM, Hopken MW, Flo-res SC, Voelkel NF: Oxidative stress in severe pulmonary hyper-tension. Am J Respir Crit Care Med. 2004;169:764-769.
14. Cracowski JL, Cracowski C, Bessard G, Pepin JL, Bessard J, Schwebel C, Stanke-Labesque F, Pison C: Increased lipid per-oxidation in patients with pulmonary hypertension. Am J Respir Crit Care Med. 2001;164:1038-1042.
15. Zhao YY, Zhao YD, Mirza MK, Huang JH, Potula HH, Vogel SM, Brovkovych V, Yuan JX, Wharton J, Malik AB: Persistent eNOS activation secondary to caveolin-1 defciency induces pul-monary hypertension in mice and humans through PKG nitra-tion. J Clin Invest. 2009;119:2009-2018.
16. Heitzer T, Krohn K, Albers S, Meinertz T: Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smok-ers: evidence for a dysfunctional nitric oxide synthase. Circ Res. 2000;86:E36-E41.
17. Higashi Y, Sasaki S, Nakagawa K, Fukuda Y, Matsuura H, Oshima T, Chayama K: Tetrahydrobiopterin enhances fore-arm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am J Hypertens. 2001;15:326-332.
18. Setoguchi S, Mohri M, Shimokawa H, Takeshita, A: Tetrahy-drobiopterin improves endothelial dysfunction in coronary mi-crocirculation in patients without epicardial coronary artery dis-ease. JAm Coll Cardiol. 2001;38:493-498.
19. Muntau AC, Röschinger W, Habich M, Demmelmair H, Hoff-mann B, Sommerhoff CP, Roscher AA: Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N Engl J Med. 2002;347:2122-2132.
20. Cerone R, Schiaffno MC, Fantasia AR, Perfumo M, Birk Moller L, Blau N: Long-term follow-up of a patient with mild tetrahydrobiopterin-responsive phenylketonuria. Mol Genet Metab. 2004;81:137-139.
21. ATS Committee on Profciency Standards for Clinical Pul-monary Function Laboratories: ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111-117.
22. Sebbag I, Rudski LG, Therrien J, Hirsch A, Langleben D: Ef-fect of chronic infusion of epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hyper-tension. Am J Cardiol. 2001;88:1060-1063.
23. Itoh T, Nagaya N, Ishibashi-Ueda H, Kyotani S, Oya H, Sakamaki F, Kimura H, Nakanishi N: Increased plasma mono-cyte chemoattractant protein-1 level in idiopathic pulmonary ar-terial hypertension. Respirology. 2006;11:158-163.
24. Girgis RE, Champion HC, Diette GB, Johns RA, Permutt S, Sylvester JT. Decreased exhaled nitric oxide in pulmonary ar-terial hypertension: response to bosentan therapy. Am J Respir Crit Care Med. 2005;172:352-357.
25. Cella G, Bellotto F, Tona F, Sbarai A, Mazzaro G, Motta G, Fareed J. Plasma markers of endothelial dysfunction in pul-monary hypertension. Chest. 2001;120:1226-1230.
26. Bogdan M, Humbert M, Francoual J, Claise C, Duroux P, Simonneau G, Lindenbaum A. Urinary cGMP concen-trations in severe primary pulmonary hypertension. Thorax. 1998;53:1059-1062
27. American Thoracic Society; European Respiratory Society: ATS/ERS recommendations for standardized procedures for the online and offine measurement of exhaled lower respiratory ni-tric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171:912-930.
28. Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, Mirrakhimov MM, Aldashev A, Wilkins MR: Silde-nafl inhibits hypoxia-induced pulmonary hypertension. Circu-lation. 2001;104:424-428.
29. Milne GL, Sanchez SC, Musiek ES, Morrow JD: Quantifca-tion of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc 2007;2:221-226.
30. Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, Zusman RM: Use of sildenafl (Viagra) in pa-tients with cardiovascular disease. ACC/AHA Expert Consen-sus Document. Circulation. 1999;99:168-177.
31. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grim-minger F, Kurzyna M, Simonneau G: Sildenafl Use in Pul-monary Arterial Hypertension (SUPER) Study Group: Silde-nafl citrate therapyfor pulmonary arterial hypertension. N Engl JMed. 2005;353:2148-2157.
32. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ: Pulmonary Arterial Hyperten-sion and Response to Tadalafl (PHIRST) Study Group: Tadalafl therapy for pulmonary arterial hypertension. Circula-tion. 2009;119:2894-2903.
33. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ: Ran-domized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257-1263.
34. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, Tarpey M, Fukai T, Harrison DG: Endothelial regulation of vasomotion in apoE-defcient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation. 2001;103:1282-1288.
35. Xue C, Johns RA: Endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333:1642-1644.
36. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D, Voelkel NF: Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159:1925-1932.
37. Xu W, Kaneko FT, Zheng S, Comhair SA, Janocha AJ, Gog-gans T, Thunnissen FB, Farver C, Hazen SL, Jennings C, Dweik RA, Arroliga AC, Erzurum SC: Increased arginase II and decreased NO synthesis in endothelial cells of patients withpulmonaryarterialhypertension. FASEB J. 2004;18:1746-1748.
38. Higashi Y, Sasaki S, Nakagawa K, Fukuda Y, Matsuura H, Oshima T, Chayama K: Tetrahydrobiopterin enhances fore-arm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am J Hypertens. 2001;15:326-332.
39. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S: Oral sildenafl is an effective and specifc pul-monary vasodilator in patients with pulmonary arterial hy-pertension: comparison with inhaled nitric oxide. Circulation. 2002;105:2398-2403.
40. Jäs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ: Bosentan Effects in iNopErable Forms of chronIc Throm-boembolic pulmonary hypertension Study Group: Bosentan for treatment of inoperable chronic thromboembolic pul-monary hypertension: BENEFiT (Bosentan Effects in iNop-Erable Forms of chronIc Thromboembolic pulmonary hyper-tension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52:2127-2134.